Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Shire Human Genetic TherapiesfiledCriticalShire Human Genetic Therapies
Publication of CL2015002906A1publicationCriticalpatent/CL2015002906A1/en
208000037265diseases, disorders, signs and symptomsDiseases0.000abstract1
Landscapes
Medical Preparation Storing Or Oral Administration Devices
(AREA)
Medicinal Preparation
(AREA)
Abstract
ADMINISTRACIÓN INTRATECAL DE COMPOSICIÓN QUE COMPRENDE UNA ENZIMA LISOSOMAL DE REEMPLAZO EN UN SUJETO SUSCEPTIBLE O CON ENFERMEDAD DE ALMACENAMIENTO LISOSOMAL; Y DISPOSITIVO PARA ADMINISTRACIÓN INTRATECAL (DIVISIONAL DE SOLICITUD 3656-2012).INTRATECAL COMPOSITION ADMINISTRATION THAT INCLUDES A REPLACEMENT LISOSOMAL ENZYME IN A SUSCEPTIBLE SUBJECT OR WITH LISOSOMAL STORAGE DISEASE; AND DEVICE FOR INTRATECAL ADMINISTRATION (APPLICATION DIVISIONAL 3656-2012).
CL2015002906A2010-06-252015-09-29
Supply to the central nervous system of therapeutic agents (divisional application 3656-2012)
CL2015002906A1
(en)
Compounds derived from thienopyrimidines, knase inhibitors mnk1 / mnk2; pharmaceutical composition; and its use for the treatment or prophylaxis of metabolic diseases, such as diabetes, kidney damage, cancer, inflammatory diseases, among others.
Use of a composition comprising a replacement enzyme for the lysosomal enzyme at a concentration greater than 5 mg / ml to treat somatic symptoms of the underlying enzyme deficiency.
Stabilized thermogelling pharmaceutical composition composed of local anesthetics with a ph of at least the pka of said anesthetics, comprising a) the basic form of one or more amide type anesthetics, b) 10 to 30% of a polyoxyethylated castor oil, and c ) at least 15% of one or more surfactants; and its method of preparation.
TREATMENT OF COGNITIVE DISORDERS WITH (R) -7-CHLORINE-N- (QUINUCLIDIN-3-IL) BENZO [B] THIOPHEN-2-CARBOXAMIDE AND PHARMACEUTICALLY ACCEPTABLE SALTS OF THE SAME
Pharmaceutical composition comprising micronized progesterone and type II safflower oil; and use for the treatment of a condition related to insufficient progesterone secretion.
Pharmaceutical composition for injection that compensates for an aqueous solution of ibuprofen and trometamol, in which the concentration of ibuprofen is between 2 and 6 mg / ml, the concentration of trometamol is between 1.8 and 5.8 mg / ml, and the pH is between 7.0 and 9.5; and its use for the treatment of pain, inflammation or fever.
Use of dronedarone to prepare a medication for the treatment of patients with arrhythmia and who have an increase in creatinine level due to the administration of dronedarone